Scarica l'app Stockscreener
6.13
3.31%
-0.21
Dopo l'orario di chiusura:
6.23
0.10
+1.63%
Precedente Chiudi:
$6.34
Aprire:
$6.59
Volume 24 ore:
834.83K
Relative Volume:
1.21
Capitalizzazione di mercato:
$118.56M
Reddito:
$1.54M
Utile/perdita netta:
$-84.53M
Rapporto P/E:
-1.0543
EPS:
-5.8145
Flusso di cassa netto:
$-73.65M
1 W Prestazione:
-14.15%
1M Prestazione:
-46.60%
6M Prestazione:
-39.72%
1 anno Prestazione:
-52.88%
Intervallo 1D:
$6.06
$6.68
Intervallo di 1 settimana:
$6.06
$7.18
Portata 52W:
$6.06
$20.56
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
Nome
Corbus Pharmaceuticals Holdings Inc
Settore
Industria
Telefono
617-963-0103
Indirizzo
500 RIVER RIDGE DRIVE, NORWOOD, MA
Compare CRBP vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
6.13 | 138.10M | 1.54M | -84.53M | -73.65M | -5.8145 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-30 | Ripresa | B. Riley Securities | Buy |
| 2025-02-28 | Iniziato | William Blair | Outperform |
| 2024-12-02 | Iniziato | Piper Sandler | Overweight |
| 2024-07-30 | Iniziato | Wedbush | Outperform |
| 2024-07-22 | Ripresa | H.C. Wainwright | Buy |
| 2024-06-26 | Iniziato | B. Riley Securities | Buy |
| 2024-06-03 | Reiterato | Oppenheimer | Outperform |
| 2024-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-03-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-09-08 | Downgrade | BTIG Research | Buy → Neutral |
| 2020-09-08 | Downgrade | Jefferies | Buy → Hold |
| 2020-09-08 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-09-08 | Downgrade | ROTH Capital | Buy → Neutral |
| 2020-07-07 | Iniziato | ROTH Capital | Buy |
| 2020-06-17 | Iniziato | BTIG Research | Buy |
| 2020-03-26 | Iniziato | Nomura | Buy |
| 2019-04-05 | Iniziato | Jefferies | Buy |
| 2019-03-20 | Iniziato | Oppenheimer | Outperform |
| 2019-01-11 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-12-26 | Iniziato | H.C. Wainwright | Buy |
| 2018-12-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2018-10-24 | Iniziato | B. Riley FBR | Buy |
| 2018-01-19 | Iniziato | Raymond James | Outperform |
| 2017-12-14 | Reiterato | Cantor Fitzgerald | Overweight |
| 2017-11-08 | Reiterato | Noble Financial | Buy |
| 2017-09-29 | Ripresa | Noble Financial | Buy |
| 2017-03-30 | Reiterato | Cantor Fitzgerald | Overweight |
| 2016-11-15 | Reiterato | JMP Securities | Mkt Outperform |
| 2016-11-11 | Reiterato | Noble Financial | Buy |
Mostra tutto
Corbus Pharmaceuticals Holdings Inc Borsa (CRBP) Ultime notizie
Corbus starts TEMPO-1. Corbus Pharmaceuticals stock has 8 Buy ratings - AD HOC NEWS
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Four parties report the same Corbus (CRBP) stake, held directly by one fund. - Stock Titan
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer - Yahoo Finance
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Why Is Corbus Pharmaceuticals (NASDAQ:CRBP) Moving Into Focus? - kalkinemedia.com
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
Is Corbus Pharmaceuticals Holdings, Inc. (CRBP) the Cannabis Stocks Stock Everyone's About to Talk About? - kalkinemedia.com
(CRBP) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
symbol__ Stock Quote Price and Forecast - CNN
What Did CANYON Study Data Show for Corbus Pharmaceuticals (NASDAQ:CRBP)? - Kalkine Media
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus Pharmaceuticals stock holds at USD 1.56 - AD HOC NEWS
Corbus Pharmaceuticals (CRBP) Edges Higher: Shares Gain 1.18% to Close at $7.74Earnings Beat Stocks - dars.gov.et
CRBP - Finviz
Is CRBP a Good Cannabis Investment After Positive Obesity Study Data? - Yahoo Finance
H.C. Wainwright Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Corbus Pharmaceuticals Holdings Inc. Stock Rallies 4.9%, Outperforms Peers - webull.com
Corbus Pharmaceuticals Insider Ben Yong Offloads 2,000 Shares at $7.84 Each (NASDAQ: CRBP) - Kalkine Media
Corbus Pharmaceuticals Holdings Inc. Stock Slides 14.4%, Underperforms Peers - webull.com
H.C. Wainwright reiterates Corbus stock rating on phase 1b data By Investing.com - Investing.com UK
Corbus CRB-913 Delivers 5% Weight Loss in Phase 1b Obesity Study - Yahoo Finance
Corbus reports phase 1b obesity drug trial results By Investing.com - Investing.com South Africa
CRBP: CRB-913 achieved 5% weight loss in 12 weeks with favorable safety, supporting further clinical development - TradingView
CRBP: CRB-913 achieved 5% weight loss in 12 weeks with mild side effects, supporting further development - TradingView
Mizuho Securities Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $33 - Moomoo
Why is Corbus Pharmaceuticals stock surging today? By Investing.com - Investing.com Canada
Form 8K Corbus Pharmaceuticals Holding For: 14 September By Investing.com - Investing.com India
Corbus Pharmaceuticals stock rises on obesity drug trial data By Investing.com - Investing.com Australia
CRBP: CRB-701 and CRB-913 show promising efficacy and safety, advancing to pivotal studies - TradingView
Corbus Pharmaceuticals stock rises on obesity drug trial data - Investing.com
Corbus Pharmaceuticals Reports Positive Topline Data From CANYON-1 Study Of Daily Oral CRB-913 For Obesity Treatment - marketscreener.com
Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga
Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity - The Manila Times
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity - Yahoo! Finance Canada
We Think Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Needs To Drive Business Growth Carefully - Moomoo
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings stock holds steady ahead of next results - AD HOC NEWS
How Corbus Pharmaceuticals Holdings Inc. (CRBP) Affects Rotational Strategy Timing - Stock Traders Daily
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Corbus Pharmaceuticals Holding (CRBP) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Corbus (CRBP) Outlook: Finishes 4.62% Higher at $10.86 for the Current Session - vinanet.vn
Corbus Pharmaceuticals Holdings, Inc. Revenue Breakdown – NASDAQ:CRBP - TradingView
CRBP’s CRB-701 Phase 3 Trial Sets the Stage for a Key Oncology Catalyst - The Globe and Mail
Corbus Pharmaceuticals Holdings Inc Azioni (CRBP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Corbus Pharmaceuticals Holdings Inc Azioni (CRBP) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Saxena Nishant C | Chief Business Officer |
Aug 11 '26 |
Buy |
9.63 |
2,600 |
25,036 |
77,900 |
| Cohen Yuval | Chief Executive Officer |
Aug 07 '26 |
Sale |
10.08 |
17,000 |
171,396 |
157,316 |
| Moran Sean F. | Chief Financial Officer |
Aug 07 '26 |
Sale |
10.08 |
12,000 |
120,971 |
84,694 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):